Grant: CIHR Fellowship
McMaster University
$63,750.00
Epigenetic regulation of hematopoietic directed differentiation in human iPS cells
FY 2012-13
Summary
The use of stem cells in regenerative medicine opens the door for major improvements in the treatment of a vast array of human diseases. In cases such as the treatment of leukemia or diabetes, it may provide solutions to the availability of compatible donors and to high quantities of cells required for transplantations. Researchers around the world, including those in our laboratory, have developed protocols to teach a stem cell to become a specialized tissue/organ cell, using various chemicals and biological reagents. Consequently, cells isolated from cord blood or even skin can be turned into stem cells, and then into bone marrow, nerve, or insulin-producing cells. Ultimately, scientists hope to to use these cells to replace damaged or ill tissues but several problems still need to be fixed before getting there. One of them is to find a way to obtain mature cells that can survive and persevere in the host for an extended period of time. Recently, our group identified a major difference existing between the adult bone marrow cells, usually isolated from a donor and used for a graft, and their laboratory engineered counterpart, obtained from stem cells. In fact, the cells produced in the laboratory maintain unusually high levels of proteins involved in the compaction of the DNA inside the nucleus of the cells. These proteins are also known to prevent the specialization and the maturation of cells in the embryo. We posit that decreasing the expression of these DNA compaction controlling proteins could greatly improve the maturation of stem cells into mature transplantable cells and their capability to repopulate or replace damaged tissues. These cells could be used in the future to treat diseases such as leukemia, lymphomas, and medullar aplasia, where a large quantity of transplantable cells can be required.
Department
Program
CIHR Fellowship
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
280510
Name
Benoit Yannick D
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Epigenetic regulation of hematopoietic directed differentiation in human iPS cells
Programtype2
Fellowship Programs
Orgnameinp2
McMaster University
Cihramount2
$63,750
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Chord Blood; Epigenetics; Hematopoietic Differentiation; Induced Pluripotent Stem Cells; Polycomb Group Proteins; Regenerative Medicine
Abstract
The use of stem cells in regenerative medicine opens the door for major improvements in the treatment of a vast array of human diseases. In cases such as the treatment of leukemia or diabetes, it may provide solutions to the availability of compatible donors and to high quantities of cells required for transplantations. Researchers around the world, including those in our laboratory, have developed protocols to teach a stem cell to become a specialized tissue/organ cell, using various chemicals and biological reagents. Consequently, cells isolated from cord blood or even skin can be turned into stem cells, and then into bone marrow, nerve, or insulin-producing cells. Ultimately, scientists hope to to use these cells to replace damaged or ill tissues but several problems still need to be fixed before getting there. One of them is to find a way to obtain mature cells that can survive and persevere in the host for an extended period of time. Recently, our group identified a major difference existing between the adult bone marrow cells, usually isolated from a donor and used for a graft, and their laboratory engineered counterpart, obtained from stem cells. In fact, the cells produced in the laboratory maintain unusually high levels of proteins involved in the compaction of the DNA inside the nucleus of the cells. These proteins are also known to prevent the specialization and the maturation of cells in the embryo. We posit that decreasing the expression of these DNA compaction controlling proteins could greatly improve the maturation of stem cells into mature transplantable cells and their capability to repopulate or replace damaged tissues. These cells could be used in the future to treat diseases such as leukemia, lymphomas, and medullar aplasia, where a large quantity of transplantable cells can be required.
Competitiondate
201302
Approvedterm2
1 yr 5 mths
Pinamesdelim
Benoit, Yannick D
Approvedterm
1 an 5 mois
Cihrcontribution2
~ $63,750~ $0~